The PhRMA Foundation has announced the recipients of $300,000 in funding for research projects that yield new strategies for assessing the value of medicines and health care services – as a part of its comprehensive Value Assessment Initiative.
Three research leaders will receive one-year grants of $100,000 each for their projects. The recipients are Louis P. Garrison, PhD, of the University of Washington; Eleanor Perfetto, PhD, of the National Health Council; and Quang A. Le, PharmD, PhD, of the Western University of Health Science.
“The recipients of this year’s Value Assessment Research Awards are the latest examples of a growing list of national leaders, supported by the Foundation, who are moving us in the right direction when it comes to delivering value in health care,” said Eileen Cannon, President of the PhRMA Foundation.
Dr. Garrison’s research project, titled “Implementing Augmented Cost-Effectiveness Analysis: Challenges and Next Steps,” will build on conventional cost-effectiveness analysis (CEA) with the aim of implementing “Augmented” CEA (ACEA), by considering additional and novel elements of value in health care. The project will include the preparation of policy papers to help advance the use of ACEA.
Dr. Perfetto’s research project, titled “Methods Principles for Using Patient-Provided Information to Improve Real-World Evidence for Patient-Centered Value Assessment,” will address current methodological limitations in value assessment by offering strategies in which patient-provided information (PPI), gathered through meaningful patient engagement, can be translated by researchers into more patient-centered research designs using real-world data sources that reflect patients’ lived experiences.
Dr. Le’s research project, titled “New Approach in Value Assessment of Health Interventions Using Doubly-Randomized Preference Trial (DRPT) Design,” will formalize methods to estimate treatment, choice, preference, and selection effects in doubly randomized preference trial (DRPT) design and evaluate these effects on health-related quality of life outcomes, with the goal of helping to enable more application of the DRPT design for assessing value of health interventions.
